Pasireotide - Mechanism of Action and Clinical Applications

Author(s): Nadia Sawicka-Gutaj, Maciej Owecki*, Marek Ruchala

Journal Name: Current Drug Metabolism

Volume 19 , Issue 10 , 2018

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: Pasireotide (SOM230) is a multi-receptor ligand somatostatin analogue (SSA) developed as the successor of the first-generation SSAs. Currently, pasireotide is recommended for the treatment of patients with Cushing's disease in whom surgery was unsuccessful, and patients with acromegaly who either remain uncontrolled after surgical therapy or in whom tumor resection is not possible.

Methods and Results: Phase II and III clinical trials have shown pasireotide efficacy in these diseases, with a similar rate of adverse events when compared with first-line SSA, although higher incidence of hyperglycemia has been observed.

Conclusion: Pasireotide therapy provides biochemical control, tumor volume reduction, and improves the quality of life in patients with those disorders. Furthermore, pasireotide might be considered as second-line therapy in patients with metastatic neuroendocrine tumors, and it also might be effective in other neoplasms with a high expression of somatostatin receptors. In addition, therapy with this novel agent has been effective in prevention of postoperative complications after pancreatectomy. However, considering the diversified responsiveness to this drug in vivo, future studies should identify factors predicting better clinical response to pasireotide.

Keywords: Pasireotide, SOM 230, acromegaly, Cushing`s disease, neuroendocrine tumors, long-acting somatostatin analogues, pituitary adenoma, growth hormone.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 14 September, 2018
Page: [876 - 882]
Pages: 7
DOI: 10.2174/1389200219666180328113801
Price: $65

Article Metrics

PDF: 72
HTML: 13